Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD's The Liver Meeting® 2023
08:57am, Friday, 10'th Nov 2023
Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due t
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
07:00am, Wednesday, 08'th Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
04:05pm, Tuesday, 17'th Oct 2023
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo
Why Akero Therapeutics Shares Are Slumping This Week
04:38pm, Thursday, 12'th Oct 2023
Akero only has one drug in clinical trials. The company said the drug didn't meet its primary endpoint of slowing NASH.
Akero (AKRO) Slumps 63% on Mixed Results From NASH Study
12:47pm, Wednesday, 11'th Oct 2023
Data from a mid-stage study shows that Akero Therapeutics' (AKRO) lead candidate failed to achieve statistical significance in its primary endpoint of fibrosis improvement in cirrhotic NASH patients.
Stocks trending October 10, 2023: Akero Therapeutics, Palantir, Hyatt Hotels
01:33pm, Tuesday, 10'th Oct 2023
Stocks are higher in early trading on dovish commentary from Federal Reserve officials. Hyatt Hotels Corporation (H) shares jump as the company will be replacing National Instruments (NATI) on the S&P
Akero Therapeutics Inc stock tanks after NASH liver treatment study disappoints
11:51am, Tuesday, 10'th Oct 2023
Akero Therapeutics Inc shares lost roughly two-thirds of their value Tuesday morning after the company released a disappointing update on its fatty liver disease treatment. A study found that just 2
Why Akero Therapeutics Stock Is Crashing Today
11:44am, Tuesday, 10'th Oct 2023
Akero's experimental NASH drug efruxifermin (EFX) missed its primary endpoint in a phase 2b study. However, statistically significant improvement was seen in NASH resolution with patients receiving EF
Biotech Stock Sinks After Disappointing Trial
11:18am, Tuesday, 10'th Oct 2023
Akero Therapeutics Inc (NASDAQ:AKRO) is plummeting to 52-week lows, after its treatment for severe fatty liver disease, efruxifermin, missed its main goal in a mid-stage trial.
Why Is Akero Therapeutics (AKRO) Stock Down 58% Today?
09:29am, Tuesday, 10'th Oct 2023
Akero Therapeutics (NASDAQ: AKRO ) stock is falling hard on Tuesday after the company failed to impress investors with its latest clinical trial results. The bad news comes from the company's Phase 2b
Akero Therapeutics shares plunge on liver disease treatment's mixed results
08:10am, Tuesday, 10'th Oct 2023
Akero Therapeutics Inc. shares AKRO, -3.56% fell more than 60% premarket on Tuesday after the company released an update on its lead product candidate, a treatment for nonalcoholic steatohepatitis, a
Akero's drug for fatty liver disease misses main trial goal
07:33am, Tuesday, 10'th Oct 2023
Akero Therapeutics said on Tuesday a mid-stage trial for its drug to treat a type of fatty liver disease showed improvement in patients, but the results were not statistically significant, sending its
Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical data Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical data
7 ‘Strong Buy' Biotech Stocks to Rejuvenate Your Portfolio
09:24pm, Wednesday, 27'th Sep 2023
While the health innovation space presents wild risks, you could potentially swing the odds in your favor with strong buy biotech stocks. Specifically, these ideas represent publicly traded biotechnol
Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
07:00am, Thursday, 31'st Aug 2023
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious meta
